HRP20150177T1 - Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva - Google Patents

Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva Download PDF

Info

Publication number
HRP20150177T1
HRP20150177T1 HRP20150177AT HRP20150177T HRP20150177T1 HR P20150177 T1 HRP20150177 T1 HR P20150177T1 HR P20150177A T HRP20150177A T HR P20150177AT HR P20150177 T HRP20150177 T HR P20150177T HR P20150177 T1 HRP20150177 T1 HR P20150177T1
Authority
HR
Croatia
Prior art keywords
preparation
accordance
intended
cells
host
Prior art date
Application number
HRP20150177AT
Other languages
English (en)
Croatian (hr)
Inventor
Jennifer Lighter
Jason Fisher
Original Assignee
Mico Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mico Bio, Inc. filed Critical Mico Bio, Inc.
Publication of HRP20150177T1 publication Critical patent/HRP20150177T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20150177AT 2007-04-12 2008-04-11 Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva HRP20150177T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92330107P 2007-04-12 2007-04-12
EP08745627.3A EP2144626B8 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same
PCT/US2008/060065 WO2008128065A2 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same

Publications (1)

Publication Number Publication Date
HRP20150177T1 true HRP20150177T1 (hr) 2015-04-10

Family

ID=39523390

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150177AT HRP20150177T1 (hr) 2007-04-12 2008-04-11 Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva

Country Status (14)

Country Link
US (3) US8394389B2 (enExample)
EP (1) EP2144626B8 (enExample)
JP (2) JP5713672B2 (enExample)
AU (1) AU2008240181B2 (enExample)
CA (1) CA2682870C (enExample)
CY (1) CY1117290T1 (enExample)
DK (1) DK2144626T3 (enExample)
ES (1) ES2531018T3 (enExample)
HR (1) HRP20150177T1 (enExample)
HU (1) HUE024427T2 (enExample)
PL (1) PL2144626T3 (enExample)
PT (1) PT2144626E (enExample)
SI (1) SI2144626T1 (enExample)
WO (1) WO2008128065A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2144626T3 (en) 2007-04-12 2015-02-09 Mico Bio Inc Tuberculosis vaccine and method of using same
DK2694101T3 (en) 2011-04-06 2017-01-09 Biovaxim Ltd Pharmaceutical compositions for the prevention and / or treatment of HIV disease in humans
WO2012137072A1 (en) 2011-04-06 2012-10-11 Biovaxim Limited Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
KR20140053887A (ko) * 2011-04-20 2014-05-08 미코 바이오, 인크. 면역 반응을 증진시키는 조성물 및 방법
ES2438690B1 (es) * 2012-06-15 2015-01-16 Fundació Institut Per A La Investigació En Ciències De La Salut "Germans Trias I Pujol" (Igtp) Unitat De Tuberculosi Experimental Micobacterias inactivadas para su uso por vía oral en la prevención de la tuberculosis
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9388400B2 (en) 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
KR101615186B1 (ko) 2014-03-07 2016-04-25 연세대학교 산학협력단 결핵 백신의 면역효과 증강용 조성물 및 면역효과 증진 방법
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
CN108743931B (zh) 2018-05-02 2022-08-16 成都威斯克生物医药有限公司 抗结核病疫苗及其制备方法和用途
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4724114A (en) 1984-04-23 1988-02-09 Kimberly-Clark Corporation Selective layering of superabsorbents in meltblown substrates
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
DE60226175T2 (de) 2001-11-14 2009-07-09 Novavax, Inc. Mycobakterieller impfstoff
WO2003075824A2 (en) 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Process of manufacturing pharmaceutical composition useful for management of tuberculosis
CA2836319A1 (en) * 2005-06-23 2006-12-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
DK2144626T3 (en) 2007-04-12 2015-02-09 Mico Bio Inc Tuberculosis vaccine and method of using same

Also Published As

Publication number Publication date
US8394389B2 (en) 2013-03-12
US9636391B2 (en) 2017-05-02
DK2144626T3 (en) 2015-02-09
AU2008240181A1 (en) 2008-10-23
WO2008128065A3 (en) 2008-12-18
WO2008128065A2 (en) 2008-10-23
US8932608B2 (en) 2015-01-13
JP5713672B2 (ja) 2015-05-07
JP2010523711A (ja) 2010-07-15
US20150258187A1 (en) 2015-09-17
EP2144626B8 (en) 2015-02-18
SI2144626T1 (sl) 2015-04-30
US20130273110A1 (en) 2013-10-17
EP2144626B1 (en) 2014-12-03
US20100112007A1 (en) 2010-05-06
PT2144626E (pt) 2015-03-03
AU2008240181B2 (en) 2014-01-09
CA2682870A1 (en) 2008-10-23
CY1117290T1 (el) 2017-04-26
EP2144626A2 (en) 2010-01-20
PL2144626T3 (pl) 2015-09-30
HUE024427T2 (en) 2016-01-28
ES2531018T3 (es) 2015-03-09
JP2015038130A (ja) 2015-02-26
CA2682870C (en) 2016-08-09

Similar Documents

Publication Publication Date Title
TW200722101A (en) Novel composition
EP2712625A3 (en) Vaccines comprising TB 10.4
Sjölander et al. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
MY126588A (en) Intranasal influenza virus vaccine
Lowell et al. Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
JP2015038130A (ja) 結核のワクチンおよびその使用方法
RU2013119946A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
JP2018501322A5 (enExample)
NZ597000A (en) Compositions and methods for administration of vaccines against dengue virus
NZ630868A (en) Acellular pertussis vaccine
MY187472A (en) Multivalent vlp conjugates
JP2014511856A5 (enExample)
WO2003007869A3 (en) Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
Szachniewicz et al. Evaluation of PLGA, lipid-PLGA hybrid nanoparticles, and cationic pH-sensitive liposomes as tuberculosis vaccine delivery systems in a Mycobacterium tuberculosis challenge mouse model–A comparison
Raska et al. DNA vaccines for the induction of immune responses in mucosal tissues
Hauge et al. A comparison of the humoral and cellular immune responses at different immunological sites after split influenza virus vaccination of mice
JP2010501595A5 (enExample)
Dou et al. Investigation of immunogenic effect of the BCG priming and Ag85A-GM-CSF boosting in Balb/c mice model
PH12022550939A1 (en) Chikungunya virus-like particle vaccine and methods of using the same
Li et al. The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis
WO2010080188A3 (en) Epitope targeted anthrax vaccine
Wales et al. Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy
EP4421174A3 (en) Adjuvant comprising a glycoarchaeol and an immunostimulant
WO2006114680A3 (en) Vaccine adjuvants